

OTCBB symbol: **SKBO**
Data as of 5/20/09 closing.
Bid **5.00** x **8.90** ask.

SKYSTAR BIO-PHARMACEUTICAL CO., LTD

Last Trade Price	\$ 8.99	<i>Shares Authorized</i>	
52-Week Range	\$ 1.00-11.50	Common Shares	20,000,000
Daily High	\$ 9.49	Preferred Shares	50,000,000
Daily Low	\$ 1.25	<i>Shares Outstanding</i>	
Market Capitalization	\$ 16.78 M	Common Shares	1,869,297
Average Volume (3 mo.)	\$ 150.794	Preferred Shares "Series A"	2,000,000

Business Summary

Skystar Bio-pharmaceutical Company ("Skystar") is one of China's leading manufacturers and distributors of vaccines and medicines for poultry, livestock and domestic pets. Skystar has over 173 products in its current product line and has over 50 more products in development. Skystar employs over 200 people in Production Facilities located in Hu Xian, Xi'an City, Shaanxi, Province, PRC.

Skystar has recently opened (July of 2006) its new GMP Certified Facility that will increase production capabilities by 200%. The demand for veterinary medicines and vaccines in China far exceeds the supply and Skystar's plan is to capitalize on its new GMP Certified Facility to increase margins while increasing production to help meet the growing and overwhelming demand for its products.

Skystar has an experienced management team, a solid and diverse customer base, proven products, key R & D relationships to develop new products that are in high demand.

Skystar was incorporated on July 3, 1997 in the PRC as a limited liability company without shares. On December 31, 2003, Skystar was restructured from a limited liability company without shares to a joint stock company limited by shares. Skystar is a high-tech enterprise, which has grown to become one of China's leading manufacturers and distributors of bio-pharmaceutical and veterinary products. Skystar Bio-Pharmaceutical (Cayman) Holdings Co., Ltd. was incorporated under the laws of the Cayman Islands on January 24, 2005. The Company is engaged in the research, development, production, marketing and sale of bio-pharmaceutical and veterinary products. All current operations of the Company are in the People's Republic of China ("China" or the "PRC"). Skystar does not conduct any substantive operations of its own and conducts its primary business operations through its variable interest entity ("VIE"), Xian Tianxing Bio-Pharmaceutical Co., Ltd. ("Xian Tianxin"). In 2005, Skystar executed a Share Exchange Agreement with the Cyber Group Network Corporation ("CGPN"), which is listed on the OTCBB, and then Skystar was restructured into Skystar Bio-pharmaceutical Company ("Skystar" or the "Company") (symbol: SKBO.OB)

With the exception of historical information, this document may include forward-looking statements that involve a number of risks and uncertainties. Actual results could differ materially from those anticipated as a result of various risks. There are numerous factors that could contribute to such differences, therefore such projected events and anticipated results are not warranties or guaranties that such events will occur or that the Company will achieve such results. For more information about this corporation and risks involved in the investment of their publicly traded shares, please see the company's website(s), and/or documents filed with the SEC, which are easily accessible in the EDGAR database system.

OTCBB symbol: **SKBO**

Skystar Bio-Pharmaceutical Company

Scott Cramer
Director - U.S. Representative
Phone: +1 (407) 645-4433

Email: scramer@skystarbio-pharmaceutical.com

Rm. 10601, Jiezuo Plaza,
No. 4, Fenghui Road
South, Gaoxin District,
Xi'an, Shaanxi Province,
P.R.China
Tel: +86 (29) 8819-3188

Website:
<http://www.skystarbio-pharmaceutical.com>

Active Market Makers

BID	ASK
NITE	NITE
DOMS	UBSS
PERT	
UBSS	

Top Market Maker by volume (Year-to-Date)

Selected Financial Data Comparison

	3 Months Ended MARCH 31, 2009	3 Months Ended MARCH 31, 2008
Total Assets	\$ 33,282,634	\$ 22,701,011
Total Liabilities	\$ 6,538,728	\$ 3,336,665
Total Expenses	\$ 639,442	\$ 490,878
Net Income (indicates loss)	\$ 1,064,644	\$ 616,351

Press Releases

[Skystar Bio-Pharmaceutical Reports First Quarter 2009 Financial Results](#)

Marketwire(Wed 9:49am) May 20, 2009

[SKYSTAR BIO-PHARMACEUTICAL CO Financials](#)

EDGAR Online Financials(Wed 9:04am) May 20, 2009

[SKYSTAR BIO-PHARMACEUTICAL CO Files SEC form 8-K, Other](#)

Events, Financial Statements and Exhibits EDGAR Online(Tue 11:21am)

[Skystar Announces 10-for-1 Reverse Stock Split and Change of Ticker Symbol to SKBO](#)

Marketwire(Tue 10:00am)

Outstanding Shares:	1,869,297
Estimated Float:	N/A
52 week high:	\$ 11.50
52 week low:	\$ 2.50
Average Volume (3-mo.)	\$ 150.794

Three Month Chart

